Instrument Inactif

Autres langues Arcede Pharma AB

Actions

ARCEDE

SE0018168742

Autres langues

04/07/24	BioStock: Arcede Pharma heading towards liquidation
22/05/24	BioStock: Full focus on financing and new CEO for Arcede
10/05/24	BioStock: New results confirmation for Arcede Pharma
08/01/24	BioStock: Arcede aims for clinic with TO1
21/12/23	BioStock: Arcede Pharma appoints acting CEO
21/12/23	Arcede Pharma Announces CEO Changes
20/11/23	BioStock: Arcede proceeds to stability study in collaboration with Iconovo
16/11/23	Iconovo and Arcede Pharma take the next step in the development of a new treatment for COPD
16/11/23	Arcede Pharma and Iconovo take the next step in the development of a new treatment for COPD
16/11/23	Arcede Pharma and Iconovo AB Takes the Next Step in the Development of a New Treatment for COPD
14/11/23	BioStock: Arcede Pharma approaches clinical trial after toxicological results
10/10/23	BioStock: Arcede Pharma's CEO on the right issue outcome
15/08/23	BioStock: Arcede hopes to reach larger market than existing drugs
30/05/23	BioStock Life Science Spring Summit with Arcede Pharma
17/05/23	BioStock: Arcede approaching dosing in tox study
28/04/23	BioStock: RSV drugs give hope to COPD patients
04/04/23	BioStock: Arcede Pharma and Iconovo receive funding from Swelife
04/04/23	Arcede Pharma and Iconovo Receive Funding from Swelife
31/03/23	Funding received from Swelife for the development of a new treatment for COPD and severe asthma
23/03/23	BioStock: Update from Arcede Pharma CEO
16/03/23	BioStock Investor Meeting with Arcede Pharma
15/02/23	BioStock: Arcede Pharma looks ahead with strengthened team
26/01/23	Notice of allowance for patent application of RCD405 in Canada
07/12/22	BioStock: Arcede Pharma prepares for clinical studies
28/11/22	BioStock: Arcede Pharma's RCD405 well tolerated